Profound Medical (TSE:PRN) Insider Thomas Michael Tamberrino Buys 13,908 Shares of Stock

Profound Medical Corp. (TSE:PRN) insider Thomas Michael Tamberrino bought 13,908 shares of the stock in a transaction on Tuesday, December 23rd. The shares were acquired at an average cost of C$9.91 per share, with a total value of C$137,828.28. Following the purchase, the insider owned 39,241 shares of the company’s stock, valued at approximately C$388,878.31. This represents a 54.90% increase in their position.

Profound Medical Trading Up 0.7%

PRN opened at C$10.78 on Friday. The company has a market cap of C$391.24 million, a P/E ratio of -8.17 and a beta of 1.19. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. The company’s 50 day moving average is C$10.11 and its 200-day moving average is C$8.34. Profound Medical Corp. has a 1-year low of C$5.23 and a 1-year high of C$12.40.

Profound Medical (TSE:PRN) last released its quarterly earnings data on Thursday, November 13th. The company reported C$0.26 earnings per share (EPS) for the quarter. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The business had revenue of C$7.36 million during the quarter. Equities research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.